Current FDA-approved treatment for AD		FDA approval (year)
Acetylcholinesterase inhibitors	Donepezil	2006
Acetylcholinesterase inhibitors	Rivastigmine	2000
NMDA antagonists	Memantine	2003
Novel medicines in clinical trials		Status
BACE1 inhibitors	E2609	Phase III
Inhibitors of APP production	Posiphen	Phase I
Tau immunotherapy	ABBV-8E12	Phase II
Aβ immunotherapy	LY3002813	Phase II
11β-HSD1 blocker	Xanamem	Phase II
p38 MAPK Alpha Inhibitor	Neflamapimod	Phase I
Butyrylcholinesterase inhibitors	Bisnorcymserine	Phase I
Angiotensin-receptor blockers	Telmisartan	Phase I
Aβ oligomer receptor antagonist	CT1812	Phase I
Mitochondrial activity and energy modulator	Oxaloacetate	Phase I
Modulators of muscarinic receptors	VU319	Phase I
Nonsteroidal estrogen	S-equol	Phase I
Nonsteroidal anti-inflammatory drugs	Salsalate	Phase I
Bcr-Abl kinase inhibitor	Nilotinib	Phase I
Modulators of protein kinase C	Bryostatin	Phase II
Insulin administered as a nasal spray	Insulin	Phase II/III